Dr Bill Campbell Compton, MD | |
17112 Laoana Dr, Eagle River, AK 99577-8505 | |
(907) 694-5824 | |
Not Available |
Full Name | Dr Bill Campbell Compton |
---|---|
Gender | Male |
Speciality | Obstetrics & Gynecology |
Location | 17112 Laoana Dr, Eagle River, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1568606804 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 769 (Alaska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Bill Campbell Compton, MD 17112 Laoana Dr, Eagle River, AK 99577-8505 Ph: (907) 694-5824 | Dr Bill Campbell Compton, MD 17112 Laoana Dr, Eagle River, AK 99577-8505 Ph: (907) 694-5824 |
News Archive
Coinciding with Stomach Cancer Awareness Month in November, the UC Santa Cruz Genomics Institute is teaming up with the patient advocacy nonprofit No Stomach For Cancer to release a web portal designed to help researchers identify individuals at risk of heritable stomach cancers.
Children's Hospital & Research Center Oakland is ranked 10th in the nation for research grants from the National Institutes of Health to children's hospitals. In 2012, Children's Hospital & Research Center Oakland received more than $15 million in awards from the NIH for 25 separate research grants - a 20.4 percent increase in funding compared to 2011.
In the vast majority of patients with advanced cancer, their muscles will gradually waste away for reasons that have never been well understood. Now, researchers reporting in the August 20 issue of Cell, a Cell Press Publication, have found some new clues and a way to reverse that process in mice. What's more, animals with cancer that received the experimental treatment lived significantly longer, even as their tumors continued to grow.
Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADEĀ® (bortezomib) for Injection, a treatment for patients with multiple myeloma.
› Verified 7 days ago